Venus Remedies Ltd
NSE: VENUSREM BSE: 526953
₹861.70
(9.99%)
Sat, 21 Mar 2026, 05:46 am
Market Cap10.49B
PE Ratio15.09
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1989
- M/s VENUS REMEDIES LTD. was incorporated as a private limited company in the name and style of Venus Glucose Pvt Ltd.
1991
- The company started its production with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana).
1994
- The company introduced Eye/Ear/Nasal Drops.
- The company expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively.
- The company was certified as 'WHO-GMP' (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana.
- The company was converted into a public limited company.
2005
- Venus Remedies successfully launches its Brand 'Ronem'
- Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd
- M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd.
- Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges.
- Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products.
- Venus Remedies sets up a wholly owned subsidiary in Germany
2006
- Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications
- Venus Remedies in-licenses product Technology from USA
2007
- Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible.
2008
- Venus facilities Accredited with European GMP Certification.
- Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria.
- Venus Remedies - European AMP Accreditation for Venus Oncology Facilities.
- Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name 'TOBRACEF' in Domestic Market for the first time globally.
2009
- Venus Remedies - Product Patent for 'TOBRACEF' granted in South Africa.
- Venus Bags Another Product Patent from South Africa for POTENTOX.
- Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101.
2010
- Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections.
- Venus Remedies receives GMP Certification from Botswana.
- Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
- The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
2011
- Venus Remedies Anti-Cancer drug 'GEMCITABINE' gets UK MHRA approval.
- Sulbactomax patent from Mexico strengthens Venus Remedies' presence in Latin America.
- Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule.
- Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
- Venus launches its patented research product ACHNIL in India.
- Venus Remedies wins 'India Manufacturing Excellence Award 2011'.
- Venus Remedies research Blockbuster 'Sulbactomax' gets European Union Patent.
2012
- VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012.
- VenusRemedis - Innovative Solution for alleviating cancer.
- Venus Remedies introduces 'Ready-to-Use' Single Vial Taxedol in India.
- Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
- The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the 'Industry 2.0 Manufacturing Innovation Conclave 2012'.
- Venus wins Patent award in Silver Category.
2013
- Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India.
- Venus Remedies signs MoU for Elores with South African pharmaceutical firm.
- Venus Remedies takes its flagship product, Elores into Latin America.
- Venus launches its first OTC product Ezenus.
- Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock.
- Venus Remedies MEROPENEM receives market authorization in Mexico.
- ELORES awarded Gold Medal for being the best Innovation of 2013
- Venus wins Innovative 100 Award for ELORES.
- Venus bags UBM India Pharma Award for Elores.
2014
- Venus ties up with Mylan for marketing meropenem in three European countries.
- VMRC Drug VRP008 to Fight 'MULTI-DRUG Resistant Bacteria' Receives European Patent.
- Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC).
2015
- Venus announces issuance of Indian Patent for Vancoplus.
- Venus Remedies holds blood, organ donation camps on its Panchkula premises.
2016
- Venus launches its second OTC product 'SWATCH GAURD' a herbal Hand Sanitizer.
2019
- Venus announces deal with Cipla for its patented product Elores for Indian Territory.
2021
- Venus Remedies launched its full-fledged Consumer Healthcare Division.
- Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India.
2022
- Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain.
- Venus remedies wins ambitionbox best places to work award.
- Venus Remedies Limited has been Great Place to Work Certified.
2023
- Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering ''Organ-on-a-Chip'' Research Model.
- Venus Remedies Limited Honored with Best Working Conditions Award 2022.
- Venus Remedies launched flagship R&D drug Elores in Oman.
- Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from four more countries.
- Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.
- Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.
2024
- Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product.
- Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme.
- Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800